Full text loading...
Buchanania lanzan (Chironji), a medicinal species of the Anacardiaceae family, exhibits antioxidant, anti-inflammatory, and antimicrobial activities. Its clinical use is limited due to low solubility, stability, and bioavailability.
To review the phytochemical profile, pharmacological activities, and nanoformulation strategies of Buchanania lanzan to enhance its therapeutic potential.
A comprehensive literature search was conducted in PubMed, Scopus, and Google Scholar for publications from 2010 to 2025 using keywords including “Buchanania lanzan”, “Chironji”, “phytochemistry”, “pharmacological activity” and, “nanoformulation.” Only peer-reviewed articles in English directly pertaining to B. lanzan were included, with emphasis on studies from the past five years. Data on plant parts, extraction methods, phytochemicals, pharmacological effects, and nanoformulations were systematically collected and categorized.
Buchanania lanzan contains multiple bioactive compounds, including flavonoids, tannins, alkaloids, glycosides, and essential oils. Nanoformulation techniques-such as polymeric nanoparticles, liposomes, nanoemulsions, and solid lipid nanoparticles-were able to improve solubility, stability, absorption, and controlled release. These strategies can potentially address bioavailability limitations and expand the plant’s applications in pharmaceuticals, nutraceuticals, and cosmeceuticals.
Nanotechnology offers promising solutions to optimize the medicinal benefits of Buchanania lanzan. Further research is required to establish clinical efficacy, standardize formulations, and enable large-scale production for broader therapeutic use.
Article metrics loading...
Full text loading...
References
Data & Media loading...